Clinical trials
HR+ Breast Cancer clinical trials
Below are recruiting hr+ breast cancer clinical trials, each written for real people, not researchers. We’re tracking 335 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07476170Recruiting
HR+/HER2- advanced breast cancer treatment patterns in China
This study looks at the real-world treatment patterns and outcomes for people with HR+/HER2- advanced breast cancer who started their first treatment in China between 2024 and 2027. It aims to understand what treatments are used and how well they work in everyday practice.
Bingjie, Beijing MunicipalityAges 18–99 - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT06417801Recruiting
Study of ESR1 gene changes in blood in advanced breast cancer
This study looks for changes in the ESR1 gene in the blood of people with advanced HR+/HER2- breast cancer. It compares these blood test results with tumor tissue results to learn more about the cancer.
Salvador, Estado de BahiaAges 18–100 - NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT07088263RecruitingPhase 3
Adaptive Chemotherapy for Advanced Breast Cancer
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
Guangzhou, GuangdongAges 18–75 - NCT06938724RecruitingPhase 2
Avoiding extra surgery in women with HER2+ or triple-negative breast cancer
This trial tests whether women with HER2-positive or triple-negative breast cancer who had a complete response to chemotherapy can safely skip radiation or additional surgery. If you had a complete tumor response after chemo and had breast-conserving surgery, you may be eligible.
MilanAges 18 years+ - NCT04119024RecruitingPhase 1
Gene-edited immune cells for advanced melanoma or solid tumors
This Phase 1 study tests a gene-modified immune cell treatment for advanced cancers that don’t have standard curative options. It may help by attacking cancer cells that show a specific marker called IL13Rα2 after patients receive “conditioning” chemotherapy to prepare the immune system.
Duarte, CaliforniaAges 18–75 - NCT07174336RecruitingPhase 3
Testing Tersolisib with other treatments for advanced breast cancer
This trial tests a new study drug called Tersolisib combined with other anti-cancer treatments for people with advanced breast cancer that has a specific gene change (PIK3CA). The goal is to see if the combination can help shrink or slow the cancer.
Anchorage, AlaskaAges 18 years+ - NCT07454499Recruiting
Symptom monitoring and health for women on hormone therapy for breast cancer
This trial tests a mobile health program to help women manage symptoms and stay healthy while taking hormone therapy (like tamoxifen or anastrozole) for early-stage breast cancer. It involves using a smartphone app and an electronic pill bottle to track your health and medication.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07117214RecruitingPhase 1
Study of a new imaging agent for breast and lung cancers
This trial tests a new imaging agent called [68Ga]Ga-DWJ155 to see how well it helps detect certain types of advanced breast cancer and non-small cell lung cancer. It may help doctors better understand the cancer and guide treatment decisions.
Groningen, Provincie GroningenAges 18–100 - NCT06950086RecruitingPhase 1/Phase 2
TYK-00540 tablets for advanced solid tumors
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07060807RecruitingPhase 3
Patritumab deruxtecan for advanced breast cancer
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
Daphne, AlabamaAges 18 years+ - NCT07407439Recruiting
Real-world study of CDK4/6 inhibitors in advanced breast cancer
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
TianjinAges 18 years+ - NCT07660055RecruitingPhase 1
Radioactive drug for advanced solid tumors
This trial tests a new radioactive drug (called 177Lu-DWJ155) that targets and kills cancer cells, along with a similar imaging agent (68Ga-DWJ155) used to see where the drug goes in the body. It is for people with certain advanced solid tumors that have not responded to standard therapies.
Omaha, NebraskaAges 18 years+ - NCT07264998Recruiting
Gut bacteria study in breast cancer patients on Abemaciclib
This study looks at how gut bacteria changes in people taking Abemaciclib (a breast cancer drug) and whether that relates to diarrhea. It may help find ways to prevent or manage this side effect.
Wuhan, HubeiAges 18–75 - NCT05416164Recruiting
Testes less radiation after a complete response to medicines
This study checks whether some people with breast cancer who have no remaining cancer after medicine (neoadjuvant systemic therapy) can safely receive less radiation. It may help reduce side effects while still keeping cancer controlled.
Amsterdam, North HollandAges 18 years+ - NCT06459791Recruiting
Personalized treatment for advanced breast cancer using lab-grown tumor models
This trial tests a personalized approach to cancer treatment. Doctors will grow a ‘mini-tumor’ from a biopsy of your cancer in the lab to help find the best therapy for you. It is for people with advanced breast cancer that has not responded well to standard treatments.
ParisAges 18 years+ - NCT05693766RecruitingPhase 2
Gene test guides treatment for hormone-positive breast cancer
This trial studies whether a gene-signature test can help guide treatment choices for people with hormone receptor–positive (ER and/or PR) breast cancer that has spread or can’t be fully removed. It may help find the best therapy approach after prior hormone therapy and targeted cancer medicine.
Birmingham, AlabamaAges 18 years+ - NCT07471750Recruiting
High-resolution imaging for routine breast cancer screening
This trial tests a new high-resolution breast imaging system during routine screening. It aims to see if the images are clear and accurate for women without breast symptoms.
Salt Lake City, UtahAges 40 years+ - NCT07467330RecruitingPhase 3
Breast cancer trial: Adding capecitabine to standard treatment
This trial tests if adding a chemotherapy drug called capecitabine to the combination of dalpiciclib and hormone therapy works better than dalpiciclib and hormone therapy alone for advanced breast cancer that is hormone receptor-positive and HER2-negative. It is for people who have not had these treatments before.
Fuzhou, FujianAges 18 years+ - NCT07817056Recruiting
Managing blood sugar side effects from inavolisib
This study looks at how to best manage high blood sugar, a common side effect of the drug inavolisib, in people with a certain type of breast cancer. It aims to help patients stay on their treatment and improve their quality of life.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06050109Recruiting
Continuing Ovarian Suppression After 5 Years
This trial checks if staying on ovarian function suppression (OFS) therapy beyond 5 years helps prevent breast cancer from coming back. It's for women with early-stage, hormone-sensitive (HR+ HER2-) breast cancer who have already completed 5 years of OFS.
Wuhan, HubeiAges 18–60 - NCT07046923RecruitingPhase 1
A study of LY4175408 for advanced cancer
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
Stanford, CaliforniaAges 18 years+
Hear when a new HR+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hr+ breast cancer?
- Yes. Clin2 currently lists 335 recruiting hr+ breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hr+ breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hr+ breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.